Albireo Pharma (ALBO) Set to Announce Quarterly Earnings on Tuesday

Share on StockTwits

Albireo Pharma (NASDAQ:ALBO) will announce its earnings results before the market opens on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter.

Albireo Pharma (NASDAQ:ALBO) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.24). The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $2.00 million. On average, analysts expect Albireo Pharma to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of ALBO traded down $0.39 on Wednesday, reaching $27.46. The stock had a trading volume of 570 shares, compared to its average volume of 33,243. The stock has a market cap of $347.37 million, a PE ratio of -8.72 and a beta of 1.74. Albireo Pharma has a 12-month low of $21.25 and a 12-month high of $39.87.

A number of research analysts have recently commented on ALBO shares. BidaskClub upgraded Albireo Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, September 1st. Wedbush restated an “outperform” rating and issued a $69.00 target price on shares of Albireo Pharma in a research note on Tuesday, August 7th. Cowen restated a “buy” rating on shares of Albireo Pharma in a research note on Wednesday, August 8th. Finally, Zacks Investment Research upgraded Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research note on Tuesday, July 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Albireo Pharma currently has a consensus rating of “Buy” and an average target price of $59.40.

In related news, insider Ronald Harold Wilfred Cooper acquired 788 shares of the stock in a transaction on Tuesday, August 14th. The stock was acquired at an average price of $31.85 per share, for a total transaction of $25,097.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.60% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Albireo Pharma stock. Bank of New York Mellon Corp raised its stake in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 205.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,263 shares of the biopharmaceutical company’s stock after buying an additional 21,685 shares during the quarter. Bank of New York Mellon Corp owned about 0.27% of Albireo Pharma worth $1,145,000 at the end of the most recent quarter. 63.44% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece was published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Fundamental Analysis and Choosing Stocks

Earnings History for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.

Leave a Reply